


# Capmatinib

03/20

**ALTERNATE NAMES:** INC280; INCB28060; INC28060; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide

**CATALOG #:** B3005-5 5 mg  
B3005-25 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>23</sub>H<sub>17</sub>FN<sub>6</sub>O

**MOLECULAR WEIGHT:** 412.4

**CAS NUMBER:** 1029712-80-8

**APPEARANCE:** Yellow solid powder

**PURITY:** >98%

**SOLUBILITY:** ~1 mg/ml in DMF  
~0.3 mg/ml in DMSO

**DESCRIPTION:** Capmatinib is an ATP competitive inhibitor of c-MET kinase or hepatocyte growth factor receptor (HGFR). Binding of Hepatocyt Growth Factor to c-MET receptor causes activation of multiple downstream pathways. Capmatinib potently inhibits *in vitro* kinase activity with an IC<sub>50</sub> of 0.13 nM. It prevents HGF-stimulated H441 cell migration with an IC<sub>50</sub> value of ~2 nM. It inhibits c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.

**STORAGE TEMPERATURE:** -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCE:** Liu, X., Wang, Q., Yang, G., et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. *Clin Cancer Res.* 17(22):7127-38 (2011).

**RELATED PRODUCTS:**

Branebrutinib (Cat. No. B2998)  
 Zanubrutinib (Cat. No. B2512)  
 Avitinib (Cat. No. B2995)  
 Avapritinib (Cat. No. B2999)  
 Theliatinib (Cat. No. B3004)

**DISCLAIMER:** **FOR RESEARCH USE ONLY! Not to be used on humans.**